Silicosis future or investigational therapies
|
Silicosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Silicosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Silicosis future or investigational therapies |
|
Risk calculators and risk factors for Silicosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Silicosis is an irreversible condition with no cure. Treatment options currently focus on alleviating the symptoms and preventing complications.
Future or Investigational Therapies
- Experimental treatments include:
- Systemic glucocorticoid therapy :
- In chronic silicosis with COPD flare up, prednisolone has been used and this resulted in statistically (although not clinically) significant improvements in lung volumes, carbon monoxide diffusing capacity, and partial pressure of arterial oxygen.[1]
- Tamoxifen citrate
- Tamoxifen citrate, a selective estrogen receptor modulator used for the treatment of breast cancer , inhibits the production of transforming growth factor-beta (TGF-b) . TGF-b has important roles in the formation of fibrosis such as the modulation of inflammation, wound repair, and immunity by decreasing lymphocyte proliferation and encouraging growth of fibroblasts. Studies about the possible effects of tamoxifen on progression, prevention, and treatment of the fibrotic pulmonary silicosis disease considering the anti-fibrotic effect shown in aforementioned studies[2]
- Whole-lung lavage can be done based on the similarity of acute silicosis and pulmonary alveolar proteinosis, although clinical utility is not very clear[3]has been found to be associated
- Inhalation of powdered aluminium, d-penicillamine and polyvinyl pyridine-N-oxide.
Previously it was shown that the action of tetrandrine is attributed to its ability to inhibit the release of reactive oxygen metabolites and inflammatory cytokines by alveolar macrophages, and that targeted delivery of tetrandrine to alveolar macrophages using a multiple emulsion system minimizes drug toxicity, maintains the drug's pharmacological activity, and enhances tetrandrine distribution in the lungs while reducing systemic drug distribution. This study provides in vivo evidence of emulsion-mediated enhancement of drug action in the lungs against silica-induced lung injury using a rat model. }}</ref>
References
- ↑ Sharma SK, Pande JN, Verma K (1991). "Effect of prednisolone treatment in chronic silicosis". Am Rev Respir Dis. 143 (4 Pt 1): 814–21. doi:10.1164/ajrccm/143.4_Pt_1.814. PMID 2008993.
- ↑ Yoldas O, Karaca T, Bilgin BC, Yilmaz OH, Simsek GG, Alici IO; et al. (2015). "Tamoxifen citrate: a glimmer of hope for silicosis". J Surg Res. 193 (1): 429–34. doi:10.1016/j.jss.2014.08.013. PMID 25218282.
- ↑ Stafford M, Cappa A, Weyant M, Lara A, Ellis J, Weitzel NS; et al. (2013). "Treatment of acute silicoproteinosis by whole-lung lavage". Semin Cardiothorac Vasc Anesth. 17 (2): 152–9. doi:10.1177/1089253213486524. PMID 23632425.